High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicentre study

C. Chabannon, K. Cornetta, J. P. Lotz, C. Rosenfeld, M. Shlomchik, S. Yanovitch, J. P. Marolleau, G. Sledge, G. Novakovitch, E. F. Srour, B. Burtness, J. Camerlo, G. Gravis, J. Lee-Fischer, C. Faucher, I. Chabbert, D. Krause, D. Maraninchi, B. Mills, L. KunkelF. Oldham, D. Blaise, P. Viens

Research output: Contribution to journalArticle

25 Scopus citations

Abstract

Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study to evaluate the use of selected peripheral blood CD34+ cells to support haematopoietic recovery following high-dose chemotherapy. Patients who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34+ cells per μl of peripheral blood underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34+ cells. For patients in the study arm, CD34+ cells were selected from aphereses using the Isolex®300 device. Fifteen patients failed to mobilize peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into two comparable groups. CD34+ cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34+ cells safely support haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.

Original languageEnglish (US)
Pages (from-to)913-921
Number of pages9
JournalBritish Journal of Cancer
Volume78
Issue number7
DOIs
StatePublished - 1998

Keywords

  • Bone marrow transplantation
  • Breast cancer
  • CD34
  • Haematopoietic stem cells
  • Mobilized blood cell
  • Tumour purging

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose chemotherapy followed by reinfusion of selected CD34<sup>+</sup> peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicentre study'. Together they form a unique fingerprint.

  • Cite this

    Chabannon, C., Cornetta, K., Lotz, J. P., Rosenfeld, C., Shlomchik, M., Yanovitch, S., Marolleau, J. P., Sledge, G., Novakovitch, G., Srour, E. F., Burtness, B., Camerlo, J., Gravis, G., Lee-Fischer, J., Faucher, C., Chabbert, I., Krause, D., Maraninchi, D., Mills, B., ... Viens, P. (1998). High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: A randomized multicentre study. British Journal of Cancer, 78(7), 913-921. https://doi.org/10.1038/bjc.1998.601